1.91
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cognition Therapeutics Inc | CGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.91 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.91 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.07 - 6.2686 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.91 | USD |
Period:
Draw Mode:
Cognition Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 55.37M | 28.99M | 21.85M | $ - | $ - | -3.13 | -0.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 3.21M | 0.30% |
Cognition Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.90 | 2.14 | 1.83 | 2.03 | 98,986 | 0.01 | 0.53% |
| 1 Month | 2.10 | 2.331 | 1.83 | 2.03 | 65,696 | -0.19 | -9.05% |
| 3 Months | 1.47 | 3.51 | 1.31 | 2.51 | 191,726 | 0.44 | 29.93% |
| 6 Months | 2.61 | 3.51 | 1.07 | 2.24 | 143,751 | -0.70 | -26.82% |
| 1 Year | 4.23 | 6.2686 | 1.07 | 2.95 | 211,159 | -2.32 | -54.85% |
| 3 Years | 12.15 | 13.80 | 1.07 | 3.91 | 186,434 | -10.24 | -84.28% |
| 5 Years | 12.15 | 13.80 | 1.07 | 3.91 | 186,434 | -10.24 | -84.28% |
Cognition Therapeutics Description
| Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. |